DOCSLIB.ORG

2018 European (IUSTI/WHO) International Union Against Sexually

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2018 European (IUSTI/WHO) International Union Against Sexually Guidelines International Journal of STD & AIDS 2018, Vol. 29(13) 1258–1272 2018 European (IUSTI/WHO) ! The Author(s) 2018 Article reuse guidelines: International Union against sexually sagepub.com/journals-permissions DOI: 10.1177/0956462418785451 transmitted infections (IUSTI) World journals.sagepub.com/home/std Health Organisation (WHO) guideline on the management of vaginal discharge Jackie Sherrard1 , Janet Wilson2, Gilbert Donders3, Werner Mendling4 and Jørgen S Jensen5 Abstract Four common pathological conditions are associated with vaginal discharge: bacterial vaginosis, aerobic vaginitis, can- didosis, and the sexually transmitted infection, trichomoniasis. Chlamydial or gonococcal cervical infection may result in vaginal discharge. Vaginal discharge may be caused by a range of other physiological and pathological conditions including atrophic vaginitis, desquamative inflammatory vaginitis, cervicitis, and mucoid ectopy. Psychosexual problems may pre- sent with recurrent episodes of vaginal discharge and vulval burning. These need to be considered if tests for specific infections are negative. Many of the symptoms and signs are non-specific and a number of women may have other conditions such as vulval dermatoses or allergic and irritant reactions. Keywords Trichomoniasis (Trichomonas vaginalis), women, diagnosis, bacterial vaginosis, candida, aerobic vaginitis, vaginal discharge Date received: 30 May 2018; accepted: 5 June 2018 Introduction Four common pathological conditions are associated with vaginal discharge: bacterial vaginosis (BV), aero- 1Department of Genitourinary Medicine, Sexual Health Department, bic vaginitis (AV), candidosis, and the sexually Buckinghamshire Healthcare NHS Trust, Amersham, UK transmitted infection, trichomoniasis. Chlamydial or 2Department of Genitourinary Medicine, Leeds Teaching Hospitals NHS gonococcal cervical infection may result in vaginal dis- Trust, Leeds, UK 3 charge. Vaginal discharge may be caused by a range of Department of Obstetrics and Gynecology, Regional Hospital H Hart Tienen, University Hospital Antwerp other physiological and pathological conditions includ- 4Infektionen in Gyn€akologie und Geburtshilfe, Wuppertal, Germany ing atrophic vaginitis, desquamative inflammatory 5Research Unit for Reproductive Microbiology, Statens Serum Institut, vaginitis (DIV), cervicitis, and mucoid ectopy. Copenhagen, Denmark Psychosexual problems may present with recurrent epi- Lead editor: Jørgen S Jensen sodes of vaginal discharge and vulval burning. These This guideline is an update of the European IUSTI vaginal discharge need to be considered if tests for specific infections are guideline 2011. negative. Many of the symptoms and signs are non-specific and a number of women may have other Corresponding author: Jackie Sherrard, Department of Genitourinary Medicine, Sexual Health conditions such as vulval dermatoses or allergic and Department, Buckinghamshire Healthcare NHS Trust, Amersham, UK. irritant reactions. Email: [email protected] Sherrard et al. 1259 Aetiology and transmission are frequent. It is not known whether AV has an infec- tious origin or whether it is an inflammatory process BV followed by a dysbiosis. It can cause long-term symp- toms with intermittent exacerbations, and recurrences BV is the commonest cause of abnormal vaginal dis- after treatment are common.8 Atrophic vaginitis in lac- charge in woman of childbearing age but may also be tating women is probably a variant of AV. More severe encountered in perimenopausal women.1,2 In forms of AV and DIV are probably the same condition. Caucasian women the prevalence is 5–15%; in Black women it is higher at 45–55%. Women who have sex with women (WSW) share similar lactobacillary types, Candidosis are more likely to have concordant vaginal microbiota More than 60% of healthy premenopausal women are (flora) patterns, and are at increased risk for BV.3 colonised with candida, with higher rates in pregnancy, BV is a dysbiosis of the vaginal microbiota. It is and lower rates in children and postmenopausal characterised by an overgrowth of predominantly women without hormonal replacement therapy.9,10 anaerobic organisms (e.g. Gardnerella vaginalis, An estimated 75% of women will experience at least Prevotella spp., Atopobium vaginae, Mycoplasma hom- one symptomatic episode during their lifetime and 6– inis, Mobiluncus spp.) in the vagina leading to a 9% will experience chronic recurrent vulvovaginal can- replacement of lactobacilli and an increase in vaginal didosis (at least four episodes per year). Vulvovaginal pH. Bacterial identification using PCR has demonstrat- candidosis results from an overgrowth of Candida albi- ed that there are many different, previously unculti- cans in 90% of women (remainder with other species, vated bacteria present in women with BV including e.g. Candida glabrata).11,12 Precipitating factors include BV-associated bacterium 1, 2, and 3, and Sneathia spe- antibiotic therapy, pregnancy, and endogenous or cies.4 Since these bacteria are difficult to culture, the exogenous immunosuppression (including diabetes antibiotic susceptibility of many is not known. mellitus and immunosuppressive medication). In some BV can arise and remit spontaneously and although women, symptoms may occur with a low burden of not strictly considered a sexually transmitted infection candida and it is thought this may be due to an allergic (STI) it is associated with sexual activity. The exact or inflammatory response to the yeast. aetiology of BV is still unclear but current evidence suggests that formation of a biofilm with G. vaginalis Trichomoniasis is important in the switch from normal vaginal flora Trichomonas vaginalis (TV) is a flagellated protozoon, to BV.5,6 which is a parasite of the genital tract. In adults, it is almost exclusively sexually transmitted. Due to site spe- AV/DIV cificity, infection only follows intravaginal or intraure- AV presents with a purulent discharge, some degree of thral inoculation of the organism. In women urethral atrophy, and vaginitis. Lactobacilli are decreased and infection is present in 90% of episodes, although the pH is elevated, but aerobic microorganisms, like urinary tract is the sole site of infection in <5% of Escherichia coli, group B streptococci, and cases. The most obvious host response to infection is Staphylococcus aureus predominate.7 Mixed infections a local increase in polymorphonuclear leucocytes. Table 1. Symptoms and signs. Bacterial vaginosis Aerobic vaginitis Candidosis Trichomoniasis Approximately 50% 10–20% asymptomatic Approx. 60% women colonised. 10–50% asymptomatic and asymptomatic Minority develop symptoms 5–15% no abnormal signs Thin white homogenous Purulent discharge Vaginal discharge may be curdy Offensive vaginal discharge in up discharge, coating walls (non-offensive) to 70% – frothy and yellow in of vagina and vestibule 10–30% Offensive fishy odour Vulval burning or stinging Vulval soreness/itching Vulval itching/irritation and erythema and erythema Absence of vaginitis Superficial dyspareunia Vulval fissuring Dysuria Vaginal erythema and Superficial dyspareunia Rarely low abdominal discomfort oedema Vaginal ulceration Satellite skin lesions Vaginitis Vulval oedema Approx. 2% ‘strawberry’ cervix visible to naked eye. 1260 International Journal of STD & AIDS 29(13) Clinical features Several studies in the last decade have shown a decrease in preterm birth, if vaginal candida colonisa- There are recognised symptoms and signs (Table 1). tion or infection had been treated with clotrimazole.39 The diagnosis of both BV and candidosis is syndromic, In a study by Holzer et al.40 women who were colonised i.e. based on clinical symptoms and signs supported by with candida spp. during the second trimester of preg- laboratory test findings, which in themselves vary in nancy had higher rates of preterm birth and lower neo- specificity and sensitivity. The classical features of TV 13,14 natal birthweight than those who were colonised are frequently absent or non-specific. during the first trimester of their pregnancy. According to old studies the vaginal treatment of an Complications asymptomatic candida colonisation during the last six Women with BV are at increased risk of acquiring weeks of pregnancy reduces the candida colonisation of STIs. They have a two-fold increased risk of HIV the newborn during vaginal delivery and thus reduces acquisition,15 1.5–2-fold risk of Chlamydia16 and gon- oral thrush and napkin dermatitis of the baby during 41 orrhoea,16 a nine-fold risk of TV,17 and a two-fold risk the first four weeks of life. Modern studies are urgent- of herpes simplex virus type 2 (HSV-2)18 compared to ly needed to confirm these findings. women without BV. HIV-positive women with BV have a three-fold risk of transmitting HIV.19 Monthly Diagnosis prophylaxis with metronidazole reduces the incidence 20 Women presenting with abnormal vulval or vaginal of STIs by almost 50%. The BV-associated bacteria symptoms should be tested to ensure that appropriate are probably also implicated in the aetiology of pelvic treatment is given.40,42–44 If this is not possible, then inflammatory disease (PID). A prospective study of examination and testing should definitely be performed women with clinically-suspected PID reported in the following situations: significant correlations between the presence of BV-associated bacteria and the presence of endometri- • Severe or recurrent symptoms 21 tis and recurrent PID. • Failure of vaginal discharge to respond to empiri- There
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Aerobic Bacterial Pathogens Causing Vaginitis in Third Trimester of Pregnancy
    Original Research Article DOI: 10.18231/2394-2754.2017.0089 Aerobic bacterial pathogens causing vaginitis in third trimester of pregnancy Indu Verma1,*, Sunita Goyal2, Vandana Berry3, Dinesh Sood4 1Associate Professor, Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala, Haryana, 2Professor and HOD, Dept. of Obstetrics and Gynecology, 3Professor and HOD, Dept. of Microbiology, Christian Medical College and Hospital, Ludhiana, Punjab, 4Professor, Dept. of Anaesthesiology, Dayanand Medical College and Hospital, Ludhiana, Punjab *Corresponding Author: Email: [email protected] Abstract Introduction: Aerobic vaginitis is defined as a disruption of the lactobacillary flora, accompanied by signs of inflammation and the presence of predominantly aerobic microflora, composed of enteric commensals or pathogens. The Lactobacilli are replaced by aerobic facultative pathogens like E.coli, Staphylococcus aureus, group B Streptococci, Klebsiella pneumonia, and Enterococcus species which lead to ascending vaginal infections and various complications of pregnancy. Aim and Objectives: To analyze the prevalence of aerobic vaginitis in third trimester of pregnancy and to study different aerobic bacterial vaginal pathogens and their antibiogram. Materials and Method: One hundred and sixty six pregnant women in the third trimester of pregnancy were studied for aerobic pathogens by gram staining and culture- sensitivity. High vaginal swab was taken of all the women and sent for culture and sensitivity. Diagnosis of aerobic vaginitis was made on microscopy and culture report. Results: Out of total 166 women, 88 were asymptomatic and 78 were symptomatic. Significant aerobic growth was seen in 29 women. Seventeen (21.79%) symptomatic women had positive vaginal culture and 12 (13.64%) asymptomatic women showed positive aerobic vaginal cultures.
    [Show full text]
  • Bacterial Vaginosis Is More Frequently Diagnosed in Women with Inflammatory Changes on Routinely Performed Papanicolaou Smear S
    Bacterial vaginosis is more frequently diagnosed in women with inflammatory changes on routinely performed Papanicolaou smear S. Baka, I. Tsirmpa, A. Chasiakou, E. Politi, I. Tsouma, A. Sianou, V. Gennimata, E. Kouskouni Department of Biopathology, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, Greece Background: Usually, most Materials/methods: Asymptomatic nonpregnant Results: A total of 1372 women (774 with laboratories reporting the results of women with or without inflammatory inflammatory and 598 without inflammation on the Pap cervical Papanicolaou (Pap) smears changes on routinely performed Pap smear and smear) with smear tests and vaginal as well tests comment on the possible recalled for cultures in the last four years were as cervical cultures participated in the study. presence of infection based on included in the study. Genital tract samples Out of the 774 women with inflammation on cytological criteria. The clinical (vaginal and cervical) were available for analysis. Pap test, 294 (38%) had negative cultures importance of these findings is Clinical specimens collected from patients were (normal flora present), while 480 (62%) unknown especially in asymptomatic inoculated onto appropriate plates for standard women had positive cultures with different women. This study was conducted to aerobic and anaerobic cultures and incubated at pathogens. In contrast, the group of women assess the possible association 37’0 C for 24h and 48h, respectively. A wet mount without inflammation on Pap test displayed between inflammatory changes as well as a gram-stained smear were examined increased percentage of negative cultures reported on Pap smears with the under microscope to obtain valuable information (63%, p<0.0001) and decreased percentage isolation of pathogens in the genital about the microorganisms present and to apply of positive cultures (37%, p<0.0001).
    [Show full text]
  • Inactivation of SARS-Cov-2 Through Treatment with the Mouth Rinsing Solutions Viruprox® and Bacterx® Pro
    microorganisms Communication Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX® and BacterX® Pro Julia Koch-Heier 1,†, Helen Hoffmann 1,†, Michael Schindler 2 , Adrian Lussi 3,4 and Oliver Planz 1,* 1 Interfaculty Institute for Cell Biology, Department of Immunology, Eberhard Karls University of Tuebingen, 72076 Tuebingen, Germany; [email protected] (J.K.-H.); [email protected] (H.H.) 2 Institute for Medical Virology and Epidemiology of Viral Disease, Department of Molecular Virology, 72076 Tuebingen, Germany; [email protected] 3 Department of Operative Dentistry and Periodontology, University Medical Centre, 79106 Freiburg, Germany; [email protected] 4 School of Dental Medicine, University of Bern, 3010 Bern, Switzerland * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic effects daily dental work. Therefore, infection control measures are necessary to prevent infection of dental personnel during dental treatments. The use of a preprocedural mouth rinse with chlorhexidine (CHX), cetylpyridinium chloride (CPC), or hydrogen peroxide (H2O2) solution for 30–60 s may reduce the viral load and may protect the personnel in a dental practice. In the present study the ® virucidal effect of the mouth rinsing solutions ViruProX with 0.05% CPC and 1.5% H2O2 and Citation: Koch-Heier, J.; Hoffmann, BacterX® pro containing 0.1% CHX, 0.05% CPC, and 0.005% sodium fluoride (F-) was investigated H.; Schindler, M.; Lussi, A.; Planz, O. in vitro. The mouth rinsing solutions successfully inactivated infectious SARS-CoV-2 particles, the Inactivation of SARS-CoV-2 through causative agent of coronavirus disease 2019 (COVID-19), within 30 s.
    [Show full text]
  • Chemical Modulators of Fibrinogen Production and Their Impact on Venous Thrombosis
    Published online: 2020-12-10 Coagulation and Fibrinolysis 433 Chemical Modulators of Fibrinogen Production and Their Impact on Venous Thrombosis Rui Vilar1 Samuel W. Lukowski1,2 Marco Garieri1 Corinne Di Sanza1 Marguerite Neerman-Arbez1,3 Richard J. Fish1 1 Department of Genetic Medicine and Development, University of Address for correspondence Richard J. Fish, Department of Genetic Geneva Faculty of Medicine, Geneva, Switzerland Medicine and Development, Faculty of Medicine, University of 2 Institute for Molecular Bioscience, The University of Queensland, Geneva, 1, rue Michel-Servet, Geneva 1206, Switzerland Saint Lucia, Queensland, Australia (e-mail: [email protected]). 3 iGE3, Institute of Genetics and Genomics in Geneva, Geneva, Switzerland Thromb Haemost 2021;121:433–448. Abstract Thrombosis is a leading cause of morbidity and mortality. Fibrinogen, the soluble substrate for fibrin-based clotting, has a central role in haemostasis and thrombosis and its plasma concentration correlates with cardiovascular disease event risk and a prothrombotic state in experimental models. We aimed to identify chemical entities capable of changing fibrinogen production and test their impact on experimental thrombosis. A total of 1,280 bioactive compounds were screened for their ability to alter fibrinogen production by hepatocyte-derived cancer cells and a selected panel was tested in zebrafish larvae. Anthralin and all-trans retinoic acid (RA) were identified as fibrinogen-lowering and fibrinogen-increasing moieties, respectively. In zebrafish larvae, anthralin prolonged laser-induced venous occlusion times and reduced thrombocyte accumulation at injury sites. RA had opposite effects. Treatment with RA, a nuclear receptor ligand, increased fibrinogen mRNA levels. Using an antisense morpholino oligonucleotide to deplete zebra- fish fibrinogen, we correlated a shortening of laser-induced venous thrombosis times with RA treatment and fibrinogen protein levels.
    [Show full text]
  • A New Approach to Treat Aerobic Vaginitis
    Advances in Infectious Diseases, 2016, 6, 102-106 Published Online September 2016 in SciRes. http://www.scirp.org/journal/aid http://dx.doi.org/10.4236/aid.2016.63013 SilTech: A New Approach to Treat Aerobic Vaginitis Filippo Murina, Franco Vicariotto, Stefania Di Francesco Lower Genital Tract Diseases Unit, V. Buzzi Hospital, University of Milan, Milan, Italy Received 26 July 2016; accepted 26 August 2016; published 29 August 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Background: The aerobic vaginitis (AV) is characterized by increased levels of aerobic bacteria, vaginal inflammation and depressed levels of lactobacilli. Objective: The purpose of this study was to investigate the therapeutic efficacy of SilTechTM vaginal softgel capsules, containing new micro- crystals of silver monovalent ions, for aerobic vaginitis (AV). Methods: This prospective study enrolled 32 women diagnosed with AV. All recruited women were treated with SilTechTM vaginal softgel capsules once daily for 7 days (one course). Therapeutic efficacy was evaluated based on clinical and microscopic criteria, and cure rates were calculated. Women who were improved (but not cured) received a second course of therapy. Patients classified with clinical and microscopic failure were treated using other strategies. Results: After one course of therapy, 59.2% (19/32) of women were cured, 19.0% (6/32) were improved (but not cured) and 21.8% (7/32) failed to re- spond to the therapy. After two courses of therapy, clinical improvement was achieved in addi- tional two women.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • Update on Vaginal Infections
    PROGRESOS DE Obstetricia y Revista Oficial de la Sociedad Española Ginecología de Ginecología y Obstetricia Revista Oficial de la Sociedad Española de Ginecología y Obstetricia Prog Obstet Ginecol 2019;62(1):72-78 Revisión de Conjunto Update on vaginal infections: Aerobic vaginitis and other vaginal abnormalities Actualización en infecciones vaginales: vaginitis aeróbica y otras alteraciones vaginales Gloria Martín Saco, Juan M. García-Lechuz Moya Servicio de Microbiología. HGU Miguel Servet. Zaragoza Abstract It is estimated that abnormal vaginal discharge cannot be attributed to a clear infectious etiology in 15% to 50% of cases. Some women develop chronic vulvovaginal problems that are difficult to diagnose and treat, even by specialists. These disorders (aerobic vaginitis, desquamative inflammatory vaginitis, atrophic vaginitis, and cytolytic vaginosis) pose real challenges for clinical diagnosis and treatment. Researchers have established Key words: a diagnostic score based on phase-contrast microscopy. We review reported evidence on these entities and Vaginitis. present our diagnostic experience based on the correlation with Gram stain. We recommend treatment with Aerobic vaginitis. an antibiotic that has a very low minimum inhibitory concentration against lactobacilli and is effective against Parabasal cells. enterobacteria and Gram-positive cocci, which are responsible for these entities (aerobic vaginitis and desqua- Diagnosis. mative inflammatory vaginitis). Resumen Se estima que entre el 15 y el 50% de las mujeres que tienen trastornos del flujo vaginal, éstos no pueden atri- buirse a una etiología infecciosa clara. Algunas de ellas desarrollarán problemas vulvovaginales crónicos difíciles de diagnosticar y tratar, incluso por especialistas. Son trastornos que plantean desafíos reales en el diagnóstico Palabras clave: clínico y en su tratamiento como la vaginitis aeróbica, la vaginitis inflamatoria descamativa, la vaginitis atrófica y la vaginitis citolítica.
    [Show full text]
  • No. 1: Aerobic Vaginitis
    SUMMER 2012 | VOLUME 5 No. 1 | Biyearly Publication Medical Diagnostic Laboratories, L.L.C. Presorted 2439 Kuser Road First-Class Mail U.S. Postage Research & Development Test Announcement Journal Watch Hamilton, NJ 08690 Aerobic Vaginitis Tests now available in the clinical Summaries of recent topical PAID Continued ...................... pg 2 laboratory publications in the medical literature Trenton, NJ Full Article ...................... pg 4 Full Article ...................... pgs 5 Permit 348 SM The Laboratorian WHAT’S INSIDE Aerobic Vaginitis P2 Aerobic Vaginitis Author: Dr. Scott Gygax, Ph.D. Femeris Women’s Health Research Center P3 Aerobic Vaginitis P3 Recent Publications Aerobic vaginitis (AV) is a state of abnormal vaginal flora forms of AV can also be referred to as desquamative that is distinct from the more common bacterial vaginosis inflammatory vaginitis (DIV). (2, 3) P4 e-quiz (BV) (Table 1). AV is caused by a displacement of the BV is a common vaginal disorder associated with the P4 Q&A healthy vaginal Lactobacillus species with aerobic pathogens overgrowth of anaerobic bacteria, a distinct vaginal such as Escherichia coli, Group B Streptococcus (GBS), P4 New Tests Announcement malodorous discharge, but is not usually associated Staphylococcus aureus, and Enterococcus faecalis that trigger with a strong vaginal inflammatory immune response. P5 Journal Watch Research & Development a localized vaginal inflammatory immune response. Clinical Aerobic Vaginitis Like AV, BV also includes an elevation of the vaginal pH signs and symptoms include vaginal inflammation, an itching P6 Classified Ad Continued ...................... pg 2 > 4.5 and a depletion of healthy Lactobacillus species. or burning sensation, dyspareunia, yellowish discharge, BV is treated with traditional metronidazole therapy that and an increase in vaginal pH > 4.5, and inflammation with targets anaerobic bacteria.
    [Show full text]